Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:01:04.395Z.
Calculation as of: 2026-10-06T15:01:04.395Z.
Quote observation: 2026-10-06T15:00:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fdfad12185ff1a6c55ef1236bc2340ccae7aa6e4dec3824b1e7761c8ffaeec30
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$2.05B
Price/OCF Ratio
11.26
TTM Avg
296.01
3Y Avg
104.86
5Y Avg
96.00
Market Cap
$2.03B
Price/OCF Ratio
5.64
TTM Avg
21.84
3Y Avg
33.85
5Y Avg
33.85
Market Cap
$2.02B
Price/OCF Ratio
11.62
TTM Avg
15.24
3Y Avg
21.44
5Y Avg
21.44
Market Cap
$2.01B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.00B
Price/OCF Ratio
12.72
TTM Avg
15.11
3Y Avg
87.88
5Y Avg
147.64
Market Cap
$2.11B
Price/OCF Ratio
12.99
TTM Avg
16.43
3Y Avg
16.61
5Y Avg
17.87
Market Cap
$2.11B
Price/OCF Ratio
N/A
TTM Avg
8.03
3Y Avg
6.03
5Y Avg
5.71
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alvotech (ALVO) | $2.05B | N/A | N/A | N/A | N/A |
| Fortrea Holdings Inc. (FTRE)vs › | $2.05B | 11.26 | 296.01 | 104.86 | 96.00 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.03B | 5.64 | 21.84 | 33.85 | 33.85 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 11.62 | 15.24 | 21.44 | 21.44 |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.01B | N/A | N/A | N/A | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.00B | 12.72 | 15.11 | 87.88 | 147.64 |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 12.99 | 16.43 | 16.61 | 17.87 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.11B | N/A | 8.03 | 6.03 | 5.71 |
| AxoGen, Inc. (AXGN)vs › | $1.96B | 209.91 | 496.06 | 363.21 | 363.21 |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.96B | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
